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Native and Multimeric Vitronectin Exhibit Similar
Affinity for Heparin
DIFFERENCES IN HEPARIN BINDING PROPERTIES INDUCED UPON DENATURATION
ARE DUE TO SELF-ASSOCIATION INTO A MULTIVALENT FORM*
(Received for publication, September 19, 1996, and in revised form, November 29, 1996)

Ping Zhuang, Anthony I. Chen, and Cynthia B. Peterson‡
From the Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee,
Knoxville, Tennessee 37996

For many years, the concept that the heparin-binding
sequence is sequestered within vitronectin and exposed
upon denaturation of the protein has guided experimental design and interpretation of related structurefunction studies on the protein. To evaluate binding of
heparin to both native and denatured/renatured vitronectin, methods for monitoring binding in solution have
been developed. A fluorescence method based on
changes in an extrinsic probe attached to heparin has
been used to evaluate heparin binding to native and
denatured/renatured vitronectin. This approach indicates that there are not major differences in intrinsic
heparin-binding affinities between native and renatured protein and invalidate the currently accepted
model for a cryptic heparin-binding sequence in the
protein. Denaturation and renaturation of vitronectin
under near physiological solution conditions is accompanied invariably by self-association of the protein into
a multimeric form (Zhuang, P., Blackburn, M. N., and
Peterson, C. B. (1996) J. Biol. Chem. 271, 14323–14332),
resulting in exposure of multiple heparin-binding sites
on the surface of the oligomer. On the basis of the binding data from solution studies and interaction of the
native monomer and the denatured multimeric form of
vitronectin with a heparin column, along with evaluation of the ionic strength dependence of heparin binding
to these vitronectin forms in solution, an alternative
model is favored to account for the altered heparin binding properties of vitronectin associated with denaturation of the protein. This model proposes that multivalent interactions between heparin and multimeric
vitronectin are responsible for differences in heparin
affinity chromatography and ionic strength dependence
compared with the native protein.

Within the circulation, complicated networks of interactions
between proteins and other macromolecules are important for
maintaining stasis. An example of the complex interplay that
must exist among these biomolecules is provided by the human
glycoprotein, vitronectin. Vitronectin interacts with a wide va* This work was supported by Grant HL50676 from the Heart, Lung,
and Blood Institute of the National Institutes of Health and by an
Established Investigator Award from the American Heart Association
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riety of ligands that are involved in control of diverse physiological processes including coagulation, fibrinolysis, tumor metastasis, the humoral immune response, and cellular migration
(reviewed in Refs. 1– 6). A partial list of target macromolecules
that interact with vitronectin includes heparin, collagen, plasminogen, plasminogen activator inhibitor-1, serine protease
inhibitor-protease complexes, and a subclass of integrin receptors on the surface of cells.
Indeed, one of the first molecules shown to interact with
vitronectin was heparin (7–11), and this interaction has since
been widely investigated (12–16). Much of the early work on
vitronectin was devoted to evaluating structural requirements
for heparin binding, including tests of the effects of denaturation or proteolysis of vitronectin on heparin binding activity.
Binding activity was evaluated from vitronectin interactions
with a heparin column, estimated in terms of the salt concentrations required to elute bound vitronectin. From these studies came a most striking observation: vitronectin binding to
heparin was enhanced upon treatment of the protein with urea,
heat, or acid (9). This phenomenon was exploited by Yatohgo et
al. (17) to develop an affinity-based purification scheme for
vitronectin that invoked chemical denaturation of bulk plasma
prior to chromatography on heparin-agarose. As early as 1984,
a model emerged in which the heparin-binding region is buried
within the native molecule, so that heparin binding is induced
when this cryptic binding site is exposed upon denaturation of
vitronectin (11, 16). This model has been generally accepted,
and more recent work has included attempts to correlate the
heparin binding properties of native and denatured/renatured
vitronectin with other functions of the protein (12, 18 –27). The
two forms of the protein, which are sometimes denoted the
“non-heparin-binding” (native) and “heparin-binding” (denatured/renatured) species, are characterized in much of the ongoing work in the field.
Many years after the initial work examining effects of denaturation on vitronectin, it was recognized that denaturation is
accompanied by self-association of the protein into a multimeric form (28, 29). Multimerization of vitronectin ensues following unfolding of the protein to a structurally altered form that
can be detected with a variety of conformationally sensitive
monoclonal antibodies (29 –31). This partially folded intermediate form has a high propensity to self-associate into multimers that do not readily interconvert with native monomers. The
net effect is that multimer formation is essentially irreversible
(32). Recently it has been shown that the process of self-association into multimers versus refolding to a monomeric form is
highly sensitive to ionic strength (31), with multimer formation
almost exclusively favored at physiological salt concentrations.
From these analyses of denaturation and self-association, it is
now clear that the vitronectin species that are commonly clas-
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Two Heparin-binding Forms of Vitronectin
sified as heparin-binding are, in fact, multimeric forms of the
protein.
The native and multimeric forms of the protein are thought
to represent the two forms that exist in vivo, with most of the
circulating pool of vitronectin in a monomeric form, whereas
matrix- and other tissue-associated forms appear to be predominantly multimeric. The hypothesis that guided this work is
that the two forms of vitronectin exhibit ligand binding properties that differ according to their function and distribution
within the body. The goal of this study was to enumerate the
energetics of heparin binding to both the native monomer and
multimeric vitronectin and to distinguish differences in heparin affinity and differences in numbers of heparin-binding sites
on the two forms of vitronectin. In addition to the affinity
chromatography approach mentioned above, other methods
that have been used previously to evaluate heparin binding to
vitronectin have either relied on indirect kinetic methods (14 –
16, 33) or assays that immobilize one or the other reactant on
a plastic surface (16, 28, 29). For a rigorous quantitative analysis of the binding of heparin to both forms of vitronectin, it
was essential to develop a solution-based method to monitor
the bimolecular interaction. This study provides the first measurements of the affinity and stoichiometry of heparin binding
to both forms of the protein using a fluorescently labeled form
of heparin to quantify the interactions.
EXPERIMENTAL PROCEDURES

Materials—Vitronectin was purified by a modification of the original
procedure of Dahlback and Podack (34), essentially as described by
Bittorf et al. (28). The molecular weight of the protein is 72,000, and the
extinction coefficient is 1.02 mlzmg21zcm21 (32). Multimeric vitronectin
was prepared by treatment of protein in 8 M urea at room temperature
for 2 h, with subsequent removal of denaturant by dialysis into 0.1 M
sodium phosphate, pH 7.4, containing 0.15 M NaCl and 1 mM EDTA
(32). Unbleached, unfractionated heparin was the kind gift of Dr.
Michael N. Blackburn (Department of Macromolecular Sciences,
SmithKline Beecham, King of Prussia, PA). Human thrombin was
provided by Dr. Frank C. Church (Department of Hematology, University of North Carolina, Chapel Hill, NC). The succinimidyl ester of
7-diethylaminocoumarin-3-carboxylic acid was acquired from Molecular Probes. Urea was a product of U. S. Biochemicals. Chromozym-TH
was purchased from Boehringer Mannheim. Sephadex G-100 Super
Fine was obtained from Pharmacia Biotech Inc. All other chemicals
were of reagent grade purity.
Preparation of Coumarin-labeled Heparin—Unbleached heparin was
fractionated by molecular weight on two columns in series of Sephadex
G-100 Super Fine (2.5 3 100 cm each) linked in series, essentially as
described (35). Fractions from the broad elution peak of heparin were
combined into separate pools, dialyzed against deionized water, and
lyophilized. For labeling with the fluorescent probe, 10 mg of fractionated heparin were dissolved in 1 ml of 0.1 M NaHCO3, pH 8.3. 7-Diethylamino-coumarin-3-carboxylic acid, succinimidyl ester (1 mg dissolved
in 100 ml of dimethylformamide) was added dropwise to the heparin
solution and incubated overnight in the dark at room temperature.
Unbound coumarin was removed by exhaustive dialysis into 0.1 M
NaHCO2, pH 8.3. Labeling stoichiometries were determined spectrophotometrically using an extinction coefficient for coumarin at 432 nm
of 57,000 M21zcm21. Heparin concentrations were determined by an
azure A dye binding method (36). Molecular weights for size-fractionated, coumarin-labeled heparin samples were determined by sedimentation equilibrium in a Beckman Optima XL-A analytical ultracentrifuge as described previously (35). For ultracentrifugation experiments,
heparin samples were dissolved in 2 M NaCl, 20 mM Tris-HCl, pH 7.4,
and a partial specific volume of 0.47 mlzg21 was used for heparin (37).
Absorbance in the ultracentrifugation experiments was monitored at
430 nm, and interference patterns were also recorded at equilibrium.
Molecular weights calculated from the absorbance and interference
optical patterns were the same within experimental error; this result
indicates that the small molecular weight probe was quantitatively
bound to the macromolecule, heparin.
Fluorescence Spectroscopy to Measure Heparin Interactions—Binding
of heparin to vitronectin was monitored by alterations in fluorescence of
the extrinsic coumarin probe that was incorporated into heparin. The
change in the fluorescent properties of the coumarin probe upon
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vitronectin binding was measured by changes either in quantum yield
or polarization. Changes in quantum yield were measured on a PerkinElmer LS-50B spectrofluorimeter, using a thermostatted cell holder
connected to an external circulating water bath. Small volume aliquots
of native vitronectin (at least 20 mgzml21) were added to a microvolume
cuvette with a 1-cm path length, containing 150 ml of the labeled
heparin sample (2.0 –30.0 mM) in 0.02 M Tris-HCl, 20 mM NaCl, pH 7.4.
Measurements of the fluorescence emission at 480 nm using an excitation wavelength of 430 nm were recorded in triplicate. The data were
mathematically corrected for dilution upon addition of vitronectin. To
evaluate binding by changes in polarization of the coumarin probe on
heparin, fluorescence anisotropy was measured with an SLM 8000
fluorimeter with film polarizers. Excitation was at 400 nm, and emission was measured at 480 nm utilizing a cut-off filter at 440 nm. Small
volume aliquots of vitronectin (10 mgzml21 stock) were titrated into 2
mM labeled heparin in 20 mM Tris buffer, pH 8.0, containing 20 mM
NaCl. The change in fluorescence anisotropy of the coumarin-labeled
heparin was monitored as a function of the total native vitronectin
concentration.
Binding constants were estimated from heparin titration data using
a nonlinear least squares computer fit to the equation:
DF 5

1
DFmax
~R 1 T 1 K 2 ~~R 1 T 1 K!2 2 4TR!2!
2R

(Eq. 1)

where DF is the change in fluorescence, R is the total concentration of
vitronectin-binding sites on heparin, T is the total titrant concentration, and K represents the dissociation constant for heparin-vitronectin
interactions (38). Fitting was performed using the Statistical Analysis
Software package.
Competitive Binding of Coumarin-labeled and Unlabeled Heparin to
Vitronectin—To determine whether the incorporation of an extrinsic
probe into heparin affects binding to vitronectin, competitive binding
studies using a fixed concentration 3 mM coumarin-labeled heparin in
the absence or the presence of 15, 45, or 75 mM unlabeled heparin were
performed. Aliquots from a concentrated stock of native vitronectin (at
least 20 mgzml21) were added to a microvolume cuvette containing a
sample of 150-ml volume. Measurements of the fluorescence emission at
480 nm with an excitation wavelength of 430 nm were recorded. The
fluorescence intensity data were mathematically corrected for dilution.
An equation analogous to that described by Bock et al. (39, 40) was
derived to analyze the competitive vitronectin binding to coumarinlabeled and unlabeled heparin, using the labeled heparin as the probe.
The equation can be written as:

S D

Ki
1
12a
@Unlabeled-Hep#
5
1
@VN#9 2 @VN#
l z Kd
a
l

(Eq. 2)

where the [Unlabeled-Hep] is the total concentration of unlabeled heparin, [VN]9 2 [VN] is the difference in the total concentration of
vitronectin required to achieve the same level of saturation in the
presence of the unlabeled heparin and in its absence, Kd and Ki are the
dissociation constants for the labeled and unlabeled heparin, respectively, l is the binding stoichiometry, and a is the fractional saturation.
The data at values of a . 0.12 were analyzed according to the equation.
Fluorescence Analysis of Chemical Denaturation of Vitronectin—Unfolding of vitronectin was induced by urea and monitored by changes in
intrinsic protein fluorescence as described (32). Protein fluorescence
measurements were made on a Perkin-Elmer LS-50B spectrofluorimeter. Emission spectra were recorded between 300 and 450 nm using an
excitation wavelength of 290 nm and a path length of 1 cm. Buffer for
the unfolding experiments was 0.1 M sodium phosphate buffer, pH 7.5,
containing 0.15 M NaCl, 1.0 mM EDTA and 0.04% (v/v) Tween 20, and
the 10 M urea stock solution was made in the same buffer. Unfolding
curves were generated from fluorescence measurements on vitronectin
incubated overnight in mixtures of the urea stock and buffer to give
solutions of intermediate urea concentrations.
Differential Scanning Calorimetry—For differential scanning calorimetry experiments, vitronectin samples were dialyzed overnight
against 0.1 M sodium phosphate buffer, pH 7.4, containing 0.15 M NaCl,
1 mM EDTA. Vitronectin solutions (0.9 mg/ml) in the absence and the
presence of added heparin (Sigma, Mr ;6000) at a 100 mM concentration
were scanned at 1 °Czmin21 using a high precision differential scanning
calorimeter (model DS-93). Samples and reference solutions were properly degassed and carefully loaded into the calorimeter to eliminate
artifacts that might arise from spurious bubbles in the solution. Reproducibility of base lines was verified by multiple overnight scans. The
analysis of the differential scanning calorimetry data was performed
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with software developed by Biocalorimetry Center (Johns Hopkins University, Baltimore, MD) (41). Absolute and excess heat capacities were
determined.
Measurement of the Rate of the Heparin-catalyzed Reaction between
Thrombin and Antithrombin—Inactivation of thrombin was measured
by the ability of antithrombin to inhibit the amidolytic activity of the
enzyme essentially as described (38). The rate of inactivation of thrombin by antithrombin plus heparin was monitored continuously by hydrolysis of the thrombin substrate, Chromozym-TH, to product that
absorbs at 405 nm. Heparin with an average molecular weight of 6000
(product of Sigma) was used in the kinetic analyses at a final concentration of 1 mgzml21. The final concentration of chromogenic substrate
was 0.19 mM, and thrombin concentration was fixed at 2 nM in the
assay. Rates of reaction using a fixed antithrombin concentration of 60
nM were measured at 30 °C in the presence of various amounts of added
vitronectin. The standard assay buffer was phosphate-buffered saline
(40 mM sodium phosphate, pH 7.4, containing 0.15 M NaCl) containing
0.1% (w/v) polyethylene glycol-8000. Absorbance at 405 nm was recorded on a Perkin-Elmer model Lambda 3B spectrophotometer interfaced with an IBM computer for automated data acquisition. Pseudofirst order rates of reaction were determined by nonlinear least squares
analysis using the IGOR software package (Wavemetrics, Oswego, OR).
RESULTS AND DISCUSSION

Because previously published methods for evaluating interactions between vitronectin and heparin have relied either on
measurements with one of the species bound to a solid phase or
on complicated kinetic experiments with multiple interactions,
a primary goal of this work was to develop a method to monitor
the binary interaction in solution. Evaluation of changes in
fluorescence of vitronectin upon interaction with heparin was
an appealing possibility, because the protein contains nine
tryptophans at positions 181, 209, 261, 294, 303, 320, 382, 405,
and 450 within the 459-amino acid chain. Note that tryptophans 320 and 382 are located in the primary sequence within
the general vicinity of the heparin-binding region, which has
been localized to amino acids 341–375 (12). However, binding of
heparin to vitronectin could not be reliably measured by
changes in fluorescence that were attributable to the
interaction.1
Binding of Vitronectin to Heparin Is Detected by Monitoring
Changes in the Fluorescence of an Extrinsic Probe on Heparin—
Because one of the goals of this research was to compare binding energetics for heparin with both monomeric and multimeric
forms of vitronectin, the strategy adopted was to introduce an
extrinsic fluorescent probe into heparin that would be sensitive
to changes in environment upon binding to either form of the
protein. Similar approaches have been previously used successfully to monitor heparin interactions with a variety of proteins,
including histidine-proline-rich glycoprotein (38), thrombin
(35, 42), antithrombin (35, 43, 44), and fibronectin (45, 46).
Fig. 1 shows binding isotherms in which coumarin-labeled
heparin was titrated with native vitronectin. The two panels of
the figure illustrate that binding of vitronectin can be measured either by changes in fluorescence intensity (Fig. 1A) or
polarization (Fig. 1B) of the coumarin probe. The quantum
yield of the coumarin probe is increased upon interaction with
vitronectin, and the steady-state anisotropy of the fluor in1
A great deal of effort was expended to determine that there is not a
reproducible change in the intrinsic fluorescence of the protein upon
binding to heparin. Initial results that indicated that vitronectin exhibits a substantial quench in fluorescence upon binding to heparin were
misleading; the quench was attributable to a loss of protein in dilute
solutions due to adsorption to the cuvette during the course of the
experiment. Potential problems stemming from adsorption of vitronectin to the surface of the cuvette were not observed in the experimental
protocol that was subsequently pursued, involving titration of a labeled
heparin sample with vitronectin. Presumably, a combination of higher
protein concentrations used for the titrations and a fixed concentration
(in the micromolar range) of the highly charged heparin sample were
sufficient to prevent substantial loss of protein during the experiment.

FIG. 1. Vitronectin binding to heparin monitored by changes
in fluorescent properties of an extrinsic coumarin probe. A presents a representative binding isotherm for native vitronectin binding
to coumarin-labeled heparin, measured by changes in fluorescence intensity at 480 nm, as described under “Experimental Procedures.” For
this titration, coumarin heparin concentration was fixed at 3.1 mM, and
the fluorescence was monitored upon additions of vitronectin from a
stock solution (20 mgzml21). The line through the data represents the
least squares fit, with a calculated dissociation constant of 5.4 3 1026 M.
The heparin sample used for this experiment had an average molecular
weight of 9600 determined by analytical ultracentrifugation. DF represents the difference between the measured fluorescence at a given
concentration of added vitronectin and the initial fluorescence of the
probe on heparin, and F represents fluorescence measured for the probe
prior to addition of vitronectin. B shows a binding isotherm measured
according to changes in fluorescence anisotropy of the coumarin probe
attached to heparin. The experiment was conducted essentially as described for A except that changes in polarization of the fluorophore were
measured. The heparin sample used for this experiment had an average
molecular weight of 6300, and its concentration was fixed at 2 mM. The
line through the data is the best fit from nonlinear least squares
analysis, yielding a dissociation constant of 4.2 3 1026 M.

creases as would be expected upon formation of a molecular
complex of larger hydrodynamic volume. The dissociation constants derived from the two equilibrium binding isotherms
shown in Fig. 1 are in excellent agreement with that calculated
from changes in intensity (Fig. 1A) equal to 5.4 3 1026 M and
that measured by polarization methods (Fig. 1B) equal to 4.2 3
1026 M.
Care was taken to establish that the coumarin probe on
heparin did not perturb the binding equilibrium with vitronectin by performing rigorous competition studies in which
vitronectin-binding isotherms with coumarin-labeled heparin
were measured in the presence and the absence of several fixed
concentrations of unlabeled heparin (Fig. 2A). These data were
used to calculate Ki, the binding constant for unlabeled heparin, and compare it with the binding constant measured for the
labeled heparin sample (Fig. 2B). From this analysis, the ratio

Two Heparin-binding Forms of Vitronectin

FIG. 2. Fluorescence titration of coumarin-labeled heparin in
the presence and the absence of unlabeled heparin. A displays
titration curves in which a fixed concentration of 3 mM labeled heparin
was titrated with native vitronectin in the absence of unlabeled heparin
(å) or in the presence of unlabeled heparin at a concentration of 15 (L),
45 (E), or 75 mM (ç). The data are expressed in terms of fractional
saturation (a). B represents a linearization of all of the data in A
exhibiting values of a . 0.12 by plotting according to Equation 2. The
fitted curves were calculated with a Kd 5 5.37 mM obtained from the
titration in the absence of unlabeled heparin (shown in A, å). The
calculated Ki equals 6.08 mM, and l, the number of protein binding sites
on the ligand, equals 1.1 from this analysis.

between the binding affinities of labeled and unlabeled heparin
samples was 1.08, indicating that the coumarin probe itself
does not affect the measured binding equilibrium. The competition studies were also important to determine the stoichiometry of interaction between the heparin sample and native
vitronectin, which is given from the y intercept of the plot of
Fig. 2B. The stoichiometry determined from simultaneous
analysis of the three competition curves in Fig. 2 was 1.1 mol of
vitronectin bound/mol heparin of molecular weight 9600. It is
important to note that size-fractionated heparins were used for
all of the experiments described in this paper, because the
number of protein binding sites will vary proportionately to the
size of the heparin chain.
Binding of Multimeric Vitronectin to Heparin Is Measured by
the Fluorescence Assays—Because previous results had indicated that structural changes induced upon denaturation of
vitronectin result in apparent higher affinity interactions with
heparin, a major objective of this study was to compare binding
of heparin with the native protein and vitronectin that had
been treated with denaturant. Recent work from this and other
laboratories (28, 29, 31, 32) has shown that alteration of
vitronectin by chemical or thermal denaturation at physiolog-

6861

FIG. 3. Heparin binding to multimeric vitronectin. A shows the
results from titration of the increase in fluorescence of the coumarin
probe on labeled heparin as multimeric vitronectin is added. DF represents the difference between the measured fluorescence at a given
concentration of added vitronectin and the initial fluorescence of the
probe on heparin, and F represents fluorescence measured for the probe
prior to addition of vitronectin. The heparin sample in this experiment
had an average molecular weight of 9600 and was fixed at a concentration of 3.1 mM. Concentration of vitronectin on the x axis is expressed as
the molar concentration of vitronectin protomers within the oligomer.
The Kd calculated from the binding isotherm is 5.1 mM. B, the stoichiometry of multimeric vitronectin binding to the ligand was determined
by titrating coumarin-labeled heparin (Mr ;9600) at a fixed concentration (30 mM) well in excess of the measured dissociation constant (5 mM)
with multimeric vitronectin. The data are expressed relative to an x
axis that corresponds to the ratio of total vitronectin added to the
cuvette to the fixed heparin concentration in the experiment. Vitronectin concentration is given as total protomers within the multimer. For
both panels, the lines through the data represent best fit lines from
nonlinear least squares analysis.

ical ionic strengths invariably produces a multimeric form of
the protein. The fluorescence methods developed in this work
for evaluating binding of heparin to native protein were also
useful for evaluating the energetics of interaction of heparin
with this multimeric form of vitronectin. Fig. 3 shows results
from a binding experiment in which increasing quantities of
vitronectin multimer were added to fixed amounts of coumarinlabeled heparin of molecular weight 9600 (same sample used in
Figs. 1A and 2 with native vitronectin). Note that the concentration of vitronectin indicated on the x axis corresponds to the
concentration of monomeric vitronectin subunits contained
within the multimer, i.e. the molar concentration of vitronectin
monomers (Mr 72,000) rather than the molar concentration of
multimeric vitronectin with an average molecular weight equal
to 420,000. The dissociation constant for heparin binding to
denatured/renatured vitronectin is calculated from the isotherm in Fig. 3A to be 5.1 3 1026 M, virtually identical to that
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TABLE I
Dissociation constants for heparin-vitronectin interactions

Vitronectin form

Buffer

Heparin molecular weightsa

[Coumarin-heparin]b
310

6

Native

20 mM Tris, pH 7.4, 20 mM NaCl
20 mM Tris, pH 7.4
Containing 20 mM NaCl
Containing 100 mM NaCl
Containing 200 mM NaCl
20 mM Tris, 20 mM NaCl
pH 6.0
pH 7.0
pH 8.0

Multimer

20 mM Tris, pH 7.4, 20 mM NaCl

20 mM Tris, pH 7.4
Containing 20 mM NaCl
Containing 100 mM NaCl
Containing 300 mM NaCl
Containing 400 mM NaCl

9600
14,800
19,800
9600

9600

7400
9600
14,800
19,800
9600

M

3.14
5.05
6.30
3.14

3.14

1.85
3.14
5.05
6.30
3.14

Kd 3 106c

nd

M

5.4 6 0.2
5.6 6 0.4
5.4 6 0.4

1.1
2.1
2.7

5.4 6 0.2
26.2 6 1.8
53.0 6 4.0

1.1
1.1
1.1

6.5 6 0.3
5.6 6 0.5
6.9 6 0.4

1.1
1.1
1.1

6.6 6 0.1
5.1 6 0.3
4.4 6 0.7
2.8 6 0.3

1.0
1.8
3.8
5.6

5.1 6 0.3
5.5 6 0.4
13.3 6 1.1
40.8 6 3.6

1.8
1.8
1.8
1.8

a
Molecular weights for unbleached, size-fractionated heparin. The molecular weights were determined by analytical ultracentrifugation as
described (35).
b
The fixed concentration of labeled heparin in the experiment. Fixed concentrations of ligand were titrated upon the addition of vitronectin to
the sample.
c
Means 6 error from the fit. Kd values were calculated according to Equation 1 under “Experimental Procedures.”
d
The parameter (n) represents the binding stoichiometry, defined as the average number of vitronectin monomers (or protomers within the
multimer) that bind to a heparin chain of a given molecular weight.

for the native protein. Table I summarizes heparin-binding
data, including dissociation constants and stoichiometries of
binding, for both the native and multimeric forms of the protein
gathered under a variety of experimental conditions.
The distinguishing feature comparing the binding of native
and multimeric vitronectin with heparin is the stoichiometry
for the protein-heparin interaction. Fig. 3B shows a titration of
coumarin-labeled heparin with multimeric vitronectin that was
performed using a fixed heparin concentration of 30 mM, which
greatly exceeds the measured Kd. Under these conditions, the
titration reaches a clear end point that is a direct measurement
of the stoichiometry of the interaction. From this analysis, the
stoichiometry of binding equals 1.8 mol of vitronectin protomer/
heparin chain. The inference from this analysis is that the
heparin-binding site within the multimeric form of the protein
spans more than one vitronectin monomer. This interpretation
of the data indicates that the binding of heparin to multimeric
vitronectin involves more intermolecular interactions than the
binding to native vitronectin at a single site on the protein.
It is also instructive to consider the results from the stoichiometry measurement reported in Fig. 3B if protein concentration is expressed in terms of the molar concentration of multimeric vitronectin. This treatment of the data yields a binding
stoichiometry of 0.4 – 0.5 mol of multimeric vitronectin/mol heparin. A stoichiometry of less than 1 is observed in many cases
for proteins binding to shorter heparin chains. This result
indicates that a binding site large enough to accommodate
multimeric vitronectin is not present on all heparins of this
size. In contrast, the binding stoichiometry for this heparin
sample with native vitronectin is nearly 1:1. This result is as
expected, because fewer molecules of larger molecular weight
multimer can be bound to heparin chains that are equal in size.
If the data in Fig. 3A are expressed in terms of moles of
multimeric vitronectin (Mr ;420,000) with the stoichiometry of
approximately 0.5, the best fit of the data yields a dissociation
constant of 0.2 3 1026 M. The tighter apparent binding affinity
results from the multiplicity of heparin-binding sites within

multimeric vitronectin.
Thermodynamics of Heparin Binding Are Similar for Native
and Multimeric Vitronectin—To further evaluate the contribution of ionic and other types of interactions to the binding of
heparin to the two forms of vitronectin, a van’t Hoff analysis
was pursued in which the temperature dependence of the binding equilibrium was evaluated for native and multimeric protein (Table II). A linear van’t Hoff relationship was observed for
both forms of vitronectin over the experimentally tested temperature range from 25 to 40 °C. For both the native and
multimeric proteins, the binding constant differs 2-fold over
the given temperature range. Small differences in the corresponding Kd values at a given temperature that are observed
comparing the native and multimeric protein are within experimental error. Because it has been established that different
types of intermolecular forces contribute differently to the enthalpic and entropic terms for a given binding equilibrium and
because these different types of interactions exhibit different
temperature dependences (47), this analysis was pursued to
evaluate the type of interactions that account for the free
energy of binding heparin to vitronectin. Enthalpic and entropic contributions to the heparin/vitronectin equilibrium, derived from the van’t Hoff analysis, are summarized in Table II.
These values are compatible with a predominance of ionic
forces in the binding interaction, as would be expected from the
highly basic nature of the heparin-binding sequence in
vitronectin and the polyelectrolytic features of heparin. This
analysis demonstrates that the energetics of interaction between heparin and either form of vitronectin are indistinguishable and that the binding interaction is dominated by enthalpic
contributions with a smaller contribution from entropic forces.
The temperature dependence of the vitronectin-heparin interaction is similar to that for the Kd of the antithrombin-heparin
interaction, which varies 1.8-fold in the range from 15 to 37 °C.
However, the situation may be contrasted with that for thrombin interactions with heparin, in which there is less of a tem-
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TABLE II
Thermodynamics of vitronectin-heparin interactions
Vitronectin
form

Native

Multimer

Experimental
Temperature

Calculated

Kd 3 10

6

°C

M

25.0
29.5
34.0
38.5
25.0
29.5
34.0
38.5

5.6 6 0.2
7.0 6 0.4
8.6 6 0.4
11.8 6 0.6
5.1 6 0.3
6.4 6 0.4
8.3 6 0.6
10.2 6 0.8

DG (25° C)

DH

Kcalzmol21

DS
calzdeg21z
mol21

7.2

9.9

9.1

7.2

9.5

7.5

perature dependence for the binding equilibrium.2
Heparin Binding Properties of Vitronectin Vary with Heparin
Chain Length—The dependence of binding on heparin chain
length was examined to determine what effects binding at
multiple sites along the chain has on the equilibrium. The data
obtained from measurements of native vitronectin binding to
three different molecular weight heparin species are shown in
Fig. 4A and summarized in Table I. It is apparent from this
analysis that the number of sites at which native vitronectin
binds on the heparin chain increases with molecular weight, as
expected. However, there is not a significant difference in the
binding affinities measured with the three different sizes of
heparins. This result indicates that vitronectin monomers bind
independently at separate sites along the heparin chain.
The question of heparin size effects is especially pertinent for
the multimeric form of the protein, in which the heparin-binding site appears to be “shared” between a minimum of two
vitronectin protomers within the multimeric protein. One
would predict that an interaction that involves multiple binding sites on both the target ligand and the protein would
exhibit tighter binding as the number of sites on the ligand
increases. Binding isotherms that describe the interaction of
multimeric vitronectin with heparins of varying size are shown
in Fig. 4B and listed in Table I. The three heparin species are
the same that were used in the measurements with native
vitronectin in Fig. 4A. In a similar fashion to the native protein,
the number of vitronectin protomers bound per heparin chain
increases with the molecular size of the heparin. Interestingly,
the molar ratio of protomers bound in multimeric vitronectin to
the ratio of native vitronectin monomers bound for a given
heparin sample is relatively constant (approximately 1.6 –2.0)
for all of the heparins tested. The consistency of the stoichiometries comparing multimeric and native vitronectin among
the heparin series is striking, and it substantiates the argument that the heparin-binding site within multimeric vitronectin encompasses more than one vitronectin polypeptide chain.
A further contrast to the independent binding behavior observed with the native protein is the observation that multimeric vitronectin exhibits progressively tighter binding to heparin as the chain length of the polysaccharide increases.
Interaction of Native or Multimeric Vitronectin with Heparin
Is Disrupted by Increases in Ionic Strength—The observation
that binding constants for heparin with native and denatured/
renatured vitronectin are essentially the same was surprising
2
The temperature dependence of the thrombin-heparin interaction
was evaluated by Olson et al. (51), along with a detailed analysis of the
ionic strength and heparin chain length dependence. These studies led
to the conclusion that thrombin binding to heparin involves nonspecific
electrostatic interactions. This study on vitronectin-heparin interaction
does not attempt to distinguish between specific or nonspecific modes of
binding. More work with discrete heparin oligosaccharides would be
necessary to make such a distinction.

FIG. 4. Molecular weight dependence of vitronectin binding to
heparin. Vitronectin binding to coumarin-labeled heparins of varying
molecular weights was measured by changes in the fluorescence intensity of coumarin probe. Binding isotherms are shown for native
vitronectin (A) and multimeric vitronectin (B). Experiments are shown
in both panels using heparin with a molecular weight of 9600 at a fixed
concentration equal to 3 mM concentration (Ç), a molecular weight of
14,800 at a fixed concentration equal to 5 mM (●), and a molecular
weight of 19800 at a fixed 6 mM concentration (E).

in light of the previous work that had indicated tighter binding
of the denatured form of vitronectin to a heparin column. To
test whether the vitronectin preparations used in this study
behaved similarly, interaction of the native and multimeric
forms of vitronectin with heparin-Sepharose was evaluated by
using a salt gradient elution. The protein is quantitatively
bound to the heparin matrix under low ionic strength conditions. Native protein was eluted in a single symmetrical peak
with a midpoint near 0.2 M NaCl. However, higher salt concentrations were required to elute multimeric vitronectin from the
heparin column, with a midpoint in the elution near 0.4 M
NaCl. Thus, similarly to previous findings, the denatured form
of vitronectin used in this study bound to a heparin column so
that a higher ionic strength was necessary for elution than that
required for the native protein.
Ionic strengh effects on the binding affinity were measured
directly using the coumarin-labeled heparin. Fig. 5A shows
titrations of coumarin-heparin with native vitronectin, and Fig.
5B shows titrations with multimeric vitronectin at various salt
concentrations. These analyses are summarized in Table I.
From these binding isotherms, it is obvious that the native and
multimeric forms of vitronectin exhibit different sensitivities to
ionic strength variations. Differences are pronounced at near
physiological NaCl concentrations, with the native form of
vitronectin exhibiting significantly weaker binding (Kd 5 ;26
mM) than the multimeric form of the protein (Kd 5 ;5 mM) at
100 mM NaCl. It should be noted that the fluorescence of the

6864

Two Heparin-binding Forms of Vitronectin

FIG. 6. Neutralization of heparin activity by the two forms of
vitronectin. Heparin activity was measured by an increase in the
reaction rate of antithrombin inactivation of thrombin. The concentration of active thrombin was monitored continuously over time by hydrolysis of the Chromozym-TH substrate as described under “Experimental Procedures.” The effects of vitronectin on the reaction kinetics
were measured at varying concentrations and are standardized to the
reaction rate of heparin-catalyzed inhibition in the absence of vitronectin. Rates measured at differing concentrations of added native
vitronectin are shown in the triangles, and rates measured with varying
amounts of added multimeric vitronectin are shown in the circles.
Concentrations of multimeric vitronectin are expressed as the concentration of constituent subunits.

FIG. 5. Ionic strength dependence of vitronectin binding to
coumarin-labeled heparin in solution. Titration of vitronectin into
a solution of labeled heparin (Mr 9600) was performed at different ionic
strengths using changes in the fluorescence of the coumarin probe on
heparin to report binding, as described under “Experimental Procedures.” The buffer solutions were 20 mM Tris, pH 7.4, containing 20 mM
NaCl (Ç), 100 mM NaCl (E), 200 mM NaCl (●), 300 mM NaCl (å), 400 mM
NaCl (M), and 500 mM NaCl (f). Binding isotherms are shown for
native vitronectin (A) and multimeric vitronectin (B). For all of the data
sets except the titration of native vitronectin at 300 mM NaCl (A, å) and
the titration of multimeric vitronectin at 500 mM NaCl (B, f), the line
through the data represents the nonlinear least square fit to the equation. The binding data gathered using the highest NaCl concentrations
in each of the two panels were sufficiently weak that a titration end
point was not reached at the concentrations of protein used in the
experiment, so a nonlinear fit to the data was precluded.

coumarin probe on free heparin (i.e. that which is not bound to
vitronectin) is not altered over the experimental ionic strength
range. The direct titrations at various ionic strengths shown in
Fig. 5 demonstrate clear differences in binding affinities in the
range from 100 to 400 mM NaCl. Higher concentrations of salt
are required to disrupt binding of multimeric vitronectin to
heparin because of the more extensive binding site that appears to be shared between at least two adjacent vitronectin
protomers. More ionic interactions contribute to the binding
of heparin to the multimeric form compared with native
vitronectin.
The Anticoagulant Activity of Heparin Is Neutralized by Either Native or Multimeric Vitronectin—It was important to
determine the effects on heparin anticoagulant activity that
resulted from the observed differences in heparin binding properties of the two forms of vitronectin. There has not been a
previous comparison of native and multimeric vitronectin in
neutralizing heparin using the kinetic assay system. To com-

pare the consequences of heparin binding by native and multimeric vitronectin on the protease inhibition, reaction kinetics
were measured using fixed concentrations of enzyme, inhibitor,
and heparin and by varying the concentration of vitronectin.
The behavior of native and multimeric vitronectin in this type
of assay is compared in Fig. 6. Native vitronectin binds and
prevents antithrombin and/or thrombin from binding to heparin in a concentration-dependent fashion. Similar inhibition
profiles have been reported previously (15, 16, 48) with a Ki of
0.6 mM for the heparin-vitronectin interaction estimated from
Dixon analysis of kinetic data (15). The results from the present study agree with this estimate, because the concentration
of native vitronectin that gives 50% inhibition is almost exactly
equal to 0.6 mM. However, another study by Preissner and
colleagues using Factor Xa rather than thrombin as the target
protease concluded that the Kd for heparin interaction with
native vitronectin was lower, equal to 1 3 1028 M (16). This
calculation was based on attempts to determine concentrations
of free and bound heparin from these assay mixtures with
multiple components, three of which bind to heparin. The validity of this approach is questionable, and the calculated Kd is
2 orders of magnitude lower than the near micromolar values
generated in the current work. Furthermore, the stated Kd is
incongruent with the kinetic data from which it is derived, in
which effects in the assay are observed using vitronectin concentrations in the micromolar range (15, 16).
For the first time, inhibition of heparin activity by multimeric vitronectin has been measured and compared with the
inhibition characteristic of native vitronectin (Fig. 6). The midpoint for inhibition for the multimer is shifted to lower
vitronectin concentrations, near 0.2 mM, compared with the 0.6
mM value observed for native vitronectin. The rather modest
difference in concentrations of the two forms of vitronectin for
inhibition of heparin activity reflects the difference in binding
affinity of native and multimeric vitronectin at physiological
ionic strength. Heparin activity is appreciably inhibited by
both forms of vitronectin, an observation that indicates that
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heparin binding to either form of the protein may be consequential for the biological activity of heparin.
The ionic strength dependence of the binding interactions
observed for native and multimeric vitronectin account for the
differences in neutralization of heparin activity in the antithrombin-thrombin assay comparing the two forms of vitronectin. The net effect of the stronger binary interaction between
heparin and multimeric versus monomeric vitronectin at physiological ionic strengths is that lower concentrations of the
multimer are required to neutralize the activity of heparin.
Heparin-like molecules exist on the lining of the vasculature
and are thought to be responsible for maintaining patency of
the blood vessels under normal circumstances. Circulating
forms of vitronectin are present in micromolar concentrations
and are predominantly the monomeric form of the protein, and
native vitronectin has the potential to modulate the anticoagulant activity of heparin or heparin-like molecules in much the
same way that other proteins that are abundant in the circulation can interfere with heparin activity (38). However, the
relative levels of circulating antithrombin (near micromolar),
combined with an affinity for heparin that is 2 orders of magnitude tighter than observed with vitronectin, effectively compete for binding of heparin so that its anticoagulant potential
in vivo is not substantially impaired by vitronectin under normal conditions. In contrast, multimeric forms of vitronectin
that are localized to the extracellular matrix and that are
released from platelets will be more effective at binding heparin and modulating its anticoagulant potential in the vicinity of
thrombi, which are localized to the vessel wall. Thus, the selfassociation of vitronectin is required to increase the number of
heparin-binding sites and effectively compete with antithrombin in circulation for heparin-like molecules at sites of vascular
injury or thrombosis.
Heparin Binding to Vitronectin Does Not Stabilize the Protein in Denaturation Experiments—The noteworthy observation that the heparin-binding sites on native and denatured/
renatured vitronectin exhibit essentially identical binding
constants for heparin, in contradiction to conclusions from most
of the earlier work that would predict large differences in
binding affinity, prompted a thorough effort to compare and
contrast interactions with native and multimeric vitronectin.
This laboratory has recently evaluated the denaturation and
renaturation/self-association process for vitronectin in detail
using spectroscopic and hydrodynamic techniques (31, 32). Reproducible unfolding curves that report changes in protein
fluorescence to characterize denaturation of vitronectin with
varying concentrations of chemical denaturants have been informative. Shown in Fig. 7A are unfolding curves observed
when intrinsic fluorescence of the protein is used to monitor
denaturation of vitronectin in the presence and the absence of
added heparin. Note that the curves do not differ using the two
different experimental conditions tested, although LeChatelier’s principle would argue for a difference between the two
curves if heparin binds preferentially to the unfolded or denatured form of vitronectin. In that case, the unfolding curve
measured in the presence of high heparin concentrations
should be shifted to lower concentrations of denaturant, reflecting the preference for heparin binding to the denatured protein
and shifting the unfolding equilibrium toward the unfolded
form at all concentrations of urea. The absence of any effect of
heparin on the unfolding curve supports the conclusion from
the binding data and strongly argues that heparin binds with
similar affinity to native and denatured vitronectin.
Similar results were obtained in thermal denaturation experiments on native vitronectin. Fig. 7B shows denaturation
endotherms for vitronectin measured in the absence and in the

6865

FIG. 7. Chemical and thermal denaturation of vitronectin
measured in the absence and the presence of heparin. A shows
curves that describe the unfolding of native vitronectin in urea, monitored by average tryptophan emission wavelength as described under
“Experimental Procedures.” Following overnight incubation of vitronectin at each concentration of urea, in the absence (●) or the presence (Ç)
of 20 mM heparin, emission spectra were recorded from 300 to 450 nm
using an excitation wavelength of 290 nm. The vitronectin concentration was 0.5 mM. The data are expressed as Fapp, the apparent fraction
unfolded. B shows the results of differential scanning calorimetric experiments on vitronectin in the presence and the absence of heparin
added in saturating concentrations. Excess heat capacity of vitronectin
is plotted on the y axis versus temperature on the x axis, measured in
the absence (solid line) and the presence (broken line) of 100 mM
heparin. Experiments are performed in 100 mM phosphate, 150 mM
NaCl, 1 mM EDTA, pH 7.4 buffer. Excess heat capacity values were
obtained according to the method described under “Experimental
Procedures.”

presence of saturating concentrations of heparin. The endotherms are indistinguishable, indicating that heparin neither
stabilizes nor destabilizes vitronectin, because preferential
binding of heparin to either form should perturb the observed
endotherm. Effects of heparin binding on stability would be
reflected in changes in the tm, the midpoint in thermal denaturation of the protein, and perhaps in the enthalpy of denaturation, measured as the area under the endotherm.
An Alternative Model to Account for Differences in Heparin
Binding Properties of Native and Multimeric Vitronectin—The
model entailing a heparin-binding sequence, which is encrypted in the native fold of vitronectin, as represented schematically in Fig. 8A, has garnered wide support because the
initial demonstration that denatured vitronectin binds more
efficiently to a heparin matrix than the starting native material (11). Although the early work on the protein clearly pointed
to differences in heparin binding properties of the two forms of
vitronectin, these differences have not been previously evaluated in a quantitative fashion. Therefore, this work represents
the first analysis of the heparin binding properties of the two
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FIG. 8. Potential models to account for the altered heparin
binding properties of denatured vitronectin. In A is an adaptation
of a model first proposed by Hayashi and co-workers (11), with strong
support to follow from Preissner and Muller-Berghaus (16), that invokes a cryptic heparin-binding site in native vitronectin. The heparin
binding site is represented by a cluster of positive charges, and intermolecular ionic interactions that are proposed to mask the heparinbinding region in native vitronectin (16) are represented by a string of
negative charges. Denaturation of the protein disrupts the proposed
intermolecular interactions that shield the region from interaction with
heparin in the native form. This model, as originally proposed, does not
incorporate multiple binding sites on the multimeric protein produced
by denaturation, although such effects do not explicitly affect the basic
premise of the model, which is a buried heparin site in native protein.
B presents an alternative model for the apparent increase in heparin
binding to denatured vitronectin. This model differs drastically from
that in A in that the heparin-binding sequence is equally exposed in
native and denatured protein. However, denaturation of the protein is
accompanied by self-association of vitronectin (28, 29, 31, 32) into a
multivalent form that contains proximal heparin-binding sites exposed
on its surface. The structural arrangement of monomers within this
multimeric form of vitronectin is unknown, so that the regular arrangement of protomers depicted with aligned heparin-binding sites is for
illustrative purposes only. According to this scheme, binding to denatured protein is apparently stronger in some binding measurements
due to the increased number of heparin-binding sites. N, N terminus; C,
C terminus.

forms of vitronectin using solution-based methods. Previously,
distinctions in the concentration of salt required to elute the
native and multimeric forms of vitronectin from a heparin
column have been noted (9, 11, 13), but these data cannot be
interpreted in a straightforward manner in terms of binding
affinity. Furthermore, immobilization of one or the other interacting species on a solid phase (e.g. matrix or plastic surface) in
many cases perturbs the binding equilibrium so that it is not
reflective of the situation in solution. Although this has not
been considered for heparin-vitronectin interactions, the problem has surfaced in evaluating vitronectin interactions with

certain other target ligands (49).
For these reasons, it was imperative that a solution-based
method for measuring heparin-vitronectin interactions be developed. Although the solution biochemistry clearly establishes
similar binding behavior for native and multimeric vitronectin,
there is obviously a difference in effective heparin binding
“affinity” for immobilized heparin and ionic strength requirements for the interaction. How can these two results be reconciled? To visualize the differences between the measured equilibria comparing monomeric and multimeric vitronectin, it is
helpful to consult the model presented in Fig. 1B. Following
denaturation and renaturation, vitronectin associates with itself to form a noncovalently linked multimeric protein. Exposed
on the surface of the protein are multiple binding sites for the
target ligand, heparin. The ionic strength and molecular
weight dependence of the binding interaction appears to be the
result of a more extensive binding site within the multimer
that incorporates features from individual heparin binding
sites on adjacent vitronectin protomers comprising the multimer. Juxtaposition of these multiple binding sites increases
their local concentration so that rebinding of the ligand following dissociation is favored. Because it is clear that there is only
a single heparin-binding site per vitronectin in its native, monomeric form, the dissociation and reassociation of heparin
from native protein is not influenced in this way. This situation
described for heparin interactions with multimeric vitronectin
is analogous in many respects to the paradigm of avidity effects
in binding of antigens to bivalent (or multivalent) antibodies, in
which effective binding of antigen to the antibody molecule is
much tighter than the measured binding affinity of the separate antigen-combining sites.
Most significantly, the model that is supported by this work
(Fig. 1B) does not involve burial of the heparin-binding site
within the native structure of the protein. Masking of the
heparin site within vitronectin has been widely accepted, despite the fact that the kinetic measurements that were used to
initially demonstrate neutralization of heparin by vitronectin
were performed using native protein and were used to calculate
Ki values representing appreciable affinity for heparin (14, 16,
33). Specific interactions with a relatively acidic region of
vitronectin near the N terminus have been proposed previously
to mask the heparin binding site in the native protein, with
little evidence to support this notion aside from charge considerations (16). As discussed above, the effectiveness of native
vitronectin in modulating the anticoagulant activity of heparin
certainly discourages application of a model in which the binding site is masked. Furthermore, the heparin-binding region of
vitronectin has recently been shown in this laboratory to be
susceptible to chemical modification with an arginine-specific
fluorescent probe (52), a result that also indicates that this
region of the protein is surface-exposed and accessible. It is
clear from this work that the heparin binding sites within
native and multimeric vitronectin are similarly exposed so that
intramolecular interactions involving the acidic region of
vitronectin cannot be envisioned to bury the heparin-binding
sequence. The two types of vitronectin should no longer be
referred to as heparin-binding or non-heparin binding; they are
more appropriately identified as native (or monomeric) and
multivalent (or multimeric) forms of vitronectin.
The physiological mechanisms that convert vitronectin from
a native to a structurally altered multimeric form with an
increased local concentration of binding sites for heparin remain elusive. Heparin binding induces conformational changes
in native vitronectin that can be detected with monoclonal
antibodies (24, 50); although such conformational changes are
generally perceived as prerequisites for the self-association of
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vitronectin leading to multimeric forms, the binding of heparin
in itself is not sufficient to induce multimerization of the protein (28, 31). Other studies using conformationally sensitive
monoclonal antibodies have indicated that most noncirculating
forms of vitronectin exist in the conformationally altered form.
From this information, it has been inferred that the form of
vitronectin found in the extracellular matrix is multimeric in
composition. Self-association to a multimeric form in the extracellular matrix may be advantageous to enhance binding of
other macromolecules known to associate with vitronectin, including plasminogen activator inhibitor-1, collagen, and heparin-like molecules. For other macromolecular interactions altered upon denaturation of vitronectin, it will be interesting to
consider whether perturbations are due to alterations in intrinsic affinity or clustering of binding sites on the multimer and
thus to clarify the importance of the observed conformational
lability of vitronectin in regulation.
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